OncoMatch/Clinical Trials/NCT07085169
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Is NCT07085169 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Trifluridine/tipiracil (TAS-102) plus bevacizumab for colo-rectal cancer.
Treatment: Trifluridine/tipiracil (TAS-102) plus bevacizumab — This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine/tipiracil (17.5 mg/m2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg/kg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: any chemotherapy
had received two or more previous chemotherapy regimens or intolerance to last regimen
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1.5x109/l, white blood count ≥3.5x109/l, platelets ≥75x109/l, hemoglobin (hb) ≥80g/l
Kidney function
serum creatinine ≤1.5x uln
Liver function
alt/ast ≤2.5x uln (for patient with liver metastasis alt/ast ≤5x uln), serum bilirubin ≤1.5x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07085169 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received any chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages